Why have ten or so nontoxic, retrovirus integrase inhibitors not been made available for AIDS treatment? A ten-year experiment must liberate them

Biomedicine and Pharmacotherapy

Volumn 53, Issue 10, 1999, Pages 484-486

  Mathe G ^a  

^a Hopital Suisse de Paris   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIFLAVINE; CYANOCOBALAMIN; ELLIPTICINE DERIVATIVE; INTEGRASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL;

EID: 0033391254     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(00)88107-X     Document Type: Letter

References (36)

1. JYN. SIDA: Trois firmes accusées de rétention de médicaments: Les pouvoirs publics sont alertés. Le Monde 1999; 25 October, p. 24.
2. Shannon WM. Prospects for chemotherapeutic or chemoprophylactic intervention in AIDS - Related retro-virus infection. In: Salzman LA, ed. Animal Models of Retrovirus Infection and Their Relationship to AIDS. Orlando: Acad Press; 1986. p. 241-64.
3. Mitsuya H, Weinhold K, Furman PA, et al. 3i-azido-3i- Deoxythymidine (BWA509U): An antiviral agent that inhibits the infectivity and cytopathic affect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 1985 ; 82 : 7096-100.
4. Olivero OA, Gomez De. Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by 3'-azido-3'-deoxythimidine [letter]. Clin Cancer Res 1998; 4: 693-6.
5. Gomez DE, Tejera AM, Olivero OA. Irreversible telomere shortening by 3'-2-3'-dideoxy thymidine (AZT treatment). Biomedic Biophys Res Commun 1998; 246: 107-10.
6. 1infected individuals remaining viraemic with Highly Active Antiretroviral Therapy (HAART). Lancet 1998; 351: 723-4.
7. 1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia and insulin resistance. Lancet 1998; 352: 1881-3.
8. 1-protease inhibitor associated lipodystrophy, hyperlipidaemia and diabetes mellitus: Cohort study. Lancet 1999; 353: 2093-9.
9. Mathé G. Human obesity and thinness, hyperlipidemia, hyperglycemia and insulin resistance associated to HIV, protease inhibitors. Prevention by alternating several antiproteases in short sequences [editorial]. Biomed Pharmacother 1999; 53: this issue.
10. 1-infection. Lancet 1994; 343: 871-81.
11. Fujiwara T, Mizauchi K. Retroviral DNA integration: Structure of an integration intermediate. Cell 1988; 54: 497-504.
12. Kreuzer KN. DNA topoisomerases as potential targets of antiviral action. Pharmac Ther 1989; 43: 377-95.
13. Mathé G, Chenu E, Bourut C. Virostatic in vivo effect of ellipticium on Friend's retrovirus infection (a model of HIV infection). Biomed Pharmacother 1990; 44: 1-3.
14. Mathé G, Chenu E, Bourut C, et al. Amino-acridines action of Friend's retrovirus in relation to their molecular ionization. Biomed Pharmacother 1989; 43: 235-6.
15. r/s genotype. In Salzman LA, ed. Animal Models of Retrovirus Infection and Their Relationship to AIDS. Orlando:Acad Press; 1986. p. 279-84.
16. Robinson HL, Miles BD, Tracy SE. Avian leukosis-induced cancer: The induction of erythroblastosis by proviral insertions into or new tranductions of c-erb B. In Salzman LA, ed. Animal Models of Retrovirus Infection and Their Relationship to AIDS. Orlando:Acad Press; 1986. p. 169-92.
17. Mathé G. Preliminary results of experimental and clinical phase I-II trials in AIDS. Combinations of Retrotranscriptase Inhibitors (RTI) and of non RTI. In: Overview and Status of HIV: Course of the Disease, Prevention and/or Control. Giornate Pavesi International Year 22. Pavia, October 1-4, 1995. p. 15.
18. 1 virostatics. Biomed Pharmacother 1998; 52: 391-6.
19. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989; 243: 1731-3.
20. Mathé G, Pontiggia P. A screening model of anti-HIV non AZT cross resistance virostatics. Biomed Pharmacother 1993: 461-4.
21. 1-AIDS complex. Biomed Pharmacother 1996; 50: 510-1.
22. Paoletti C, Le Peck JB, Dat-Xuong N, et al. Antitumor activity, pharmacology and toxicity of ellipticines, ellipticium, and 9-hydroxyderivatives: Preliminary clinical trials of 2 methy - 9-hydroxy ellipticinium. Recent Results Cancer Res 1980; 74: 107-10.
23. Boyd ML. Treatment of early anterior urethritis with acriflavine. Urol Cutan Rev 1930; 34: 303-6.
24. Assinder EU, Birm MD. Acriflavine as urinary antiseptic. Lancet 1936; Feb 8th: 304-6.
25. Gouvette A, Huertas D, Droz JP, Rouesse J, Amiel JL. Pharmacokinetics of 2-methyl-9 hydroxy-ellipticin acetate in cancer patients. Eur J Cancer Clin. Oncol 1982; 18: 1285-92.
26. Lesca P, Lecointe P, Paoletti C, Mansuy D. Ellipticine as potent inhibitors of aryl hydrocarbon hydroxylase: Their binding to microsomal cytochrome P450 and protective effect against benzo (a) pyrene mutagenicity. Biochem Pharmacol; 27: 1203-9.
27. Davis RH, Williams H, Smith HJ. Intermolecular forces and stereospecificity in drug action. In: Introduction to the Principal of Drug Design. London: Wright; 1988.
28. Dariosecq JM, Girard PM. Antirétroviraux. Paris : Mémento Thérapeutique; 1995.
29. Brown MS, Anderson RG, Goldstein JL. Recycling receptors: The round-trip itinerary of migrant membrane protein. Cell 1983; 32: 663-7.
30. 1 load regression (induced by an original model of 4 virostatic combinations) leads to minimal residual disease < 20 RNA copies, but perceptible owing to virus rebounds associated to classical AIDS cofactor. Xth Symposium on HIV Infection, Toulon, June 17-19, 1999.
31. Fesen MR, Kohn KW, Letreurtre F, Pommier Y. Inhibitors of human immunodeficiency virus integrase. Proc Natl Acad Sci USA 1993; 90: 2403.
32. Carteau S, Mouscadet JF, Goulaonic P, Subra F, Auclair C. Effect of topoisomerase inhibitors on the in vitro HIV-DNA integration reaction. Biochem Biophys Res Commun 1993; 192: 1409-14.
33. Mathé G. Red wine, green tea and vitamins: Do their antioxydants play a role in immunologie protection against cancer and AIDS. Biomed Pharmacother 1999; 53: 165-7.
34. 1- Integrase inhibitors. Pharm Res 1996; 13: 1892-5.
35. 1-DNA into cellular DNA. Biochem Biophys Res Commun 1998; 246: 393-7.
36. Hazada DJ, Felock PJ, Hasting JC, Pramanik B, Wolfe AL. Differential divalent cation requirement uncouple the assembly and catalytic reactions in human immunodeficiency virus type 1 integrase. J Virol 1997; 71: 7005-11.